Patient Advocacy White Paper

Patient Advocacy: A strategic function within the company that serves as a connection point between the patient community and the company, serving to raise awareness of a disorder and possible therapies, facilitating a free flow of information, and helping to discover and address patients’ unmet needs.

The BioNJ Patient Advocacy Advisory Committee has partnered with Merrill DataSite to create a comprehensive white paper regarding the importance of patient advocacy as a strategic function in New Jersey’s  pharmaceutical and biotechnology companies. Following a member survey and webinar, the Committee shares best practices and relevant steps for companies with fledgling patient advocacy departments or those companies contemplating one.  The culmination of this effort is a study that brings to light the current realities and future prospects of patient advocacy.

To receive the white paper, Patient Advocacy: An Emerging Role Within Pharma & Biotechnology, please submit your information below.

Name (required)

Email (required)

Company (required)

Position (required)

Address (required)

Phone (required)

Patient Advocacy Committee Members

Jayne Gershkowitz, Vice President, Patient Advocacy & Public Policy, Amicus Therapeutics
Cara Thompson, Director, Patient Advocacy, Celgene Corporation
Tamara L. Atkins, MBA, State Alliance Manager, Northeast Region, ImClone Systems Corporation, a wholly-owned subsidiary of Eli Lilly and Co.
Tracy Henrikson, VP, Corporate Communications, ImClone Systems Corporation, a wholly-owned subsidiary of Eli Lilly and Co.
Diane Goetz, Senior Director of Patient & Professional Advocacy, PTC Therapeutics
Elizabeth Brewer, MS, MPH, Director, Government Healthcare & State Affairs, Sanofi